Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
01
Overview
Shenrong (also known as Shenrong Granules) is a traditional Chinese herbal medicine developed by Shijiazhuang Yiling Pharmaceutical and Hebei Yiling Hospital. It is formulated as an oral granule and is currently in Phase II clinical development for the treatment of amyotrophic lateral sclerosis (ALS) with the Chinese medicine pattern of 'Duyuan deficiency syndrome'. Derived from a long-standing in-hospital preparation (Jiweiling Capsule), Shenrong is a multi-herb mixture containing ingredients such as ginseng, deer antler, astragalus, and epimedium. It is designed to exert neuroprotective, anti-inflammatory, and anti-apoptotic effects, helping to slow down motor neuron degeneration and muscle atrophy in ALS patients.
- Other names
- Shenrong GranulesShenrong Keli参蓉颗粒
Beyond the preview
Go deeper on Shenrong.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenrong.
Work on Shenrong? Claim this page to correct or add information. Claim this page